Fact Sheet PDF

Share Graph

Share Data

20/12/2024

Currency	JPY
Previous Close	2,376
Change (%)	-0.71

Volume	969,300
Number of Shares ( mil)	525.63
Market Cap ( mil)	1,248,644.75

Latest press releases

09/12/2024	Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting
21/11/2024	Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
01/11/2024	Announcement Regarding the Transfer of Sales from Kyowa Kirin to LEO Pharma Following the Termination of the Distribution and Co-Promotion Agreement for the Psoriasis Vulgaris Treatment "Dovobet® Ointment, Gel, and Foam” in Japan
31/10/2024	Notice Regarding Changes of Representative Directors
31/10/2024	Announcement of Consolidated Financial Results Fiscal 2024 Third Quarter
24/10/2024	A Faculty Member of the School of Life Science and Technology, Institute of Science Tokyo has been Appointed as a Researcher at Kyowa Kirin through the Cross-Appointment System.
01/08/2024	Announcement of Consolidated Financial Results Fiscal 2024 Second Quarter
01/08/2024	Announcement regarding the restructuring of APAC region business and Change in a Specified Subsidiary
01/08/2024	Notice of Transition to a Research Organization to Realize Our Vision toward 2030, and Introduction of a Voluntary Retirement Program
29/07/2024	Kyowa Kirin Joins the Pharmaceutical Supply Chain Initiative (PSCI)
01/07/2024	Orchard Therapeutics Celebrates Global Progress toward Advancing Newborn Screening for MLD on International Neonatal Screening Day
28/06/2024	Kyowa Kirin Announces Application for Additional Formulation of “LUMICEF® Subcutaneous Injection 210 mg Pen” in Japan

Company presentation

Kyowa Kirin is an R&D-based life sciences company with special strengths in biotechnology. The Kyowa Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.